




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Journal of Cardiothoracic and Vascular Anesthesia

journal homepage: [www.jcvaonline.com](http://www.jcvaonline.com)

# High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysis

Rachel Si Jing Tan, (RT)\*, Ka Ting Ng, (KN)\*<sup>1</sup>,  
Chua Ee Xin, (CE)<sup>†</sup>, Rafidah Atan, (RA)\*,  
Nor'azim Mohd Yunos, (NMY)\*, M. Shahnaz Hasan, (MH)\*

\*Department of Anesthesiology, Faculty of Medicine, Universiti Malaya, 50603 Kuala Lumpur, Malaysia

<sup>†</sup>Queen Elizabeth Hospital, Kota Kinabalu, Malaysia

## ABSTRACTS

**Objectives:** The clinical efficacy of corticosteroids remains unclear. The primary aim of this systematic review and meta-analysis was to evaluate the use of high-dose versus low-dose corticosteroids on the mortality rate of COVID-19 patients.

**Design:** Systematic review and meta-analysis.

**Setting:** Electronic search for randomized controlled trials and observational studies (MEDLINE, EMBASE, CENTRAL).

**Participants:** Hospitalized adults  $\geq 18$  years old who were SARS-CoV-2 PCR positive.

**Interventions:** High-dose and low-dose corticosteroids.

**Measurements and Main Results:** A total of twelve studies (n=2759 patients) were included in this review. The pooled analysis demonstrated no significant difference in mortality rate between the high-dose and low-dose corticosteroids groups (n=2632; OR: 1.07 [95%CI 0.67, 1.72], p=0.77, I<sup>2</sup>=76%, trial sequential analysis=inconclusive). No significant differences were observed in the incidence of intensive care unit (ICU) admission rate (n=1544; OR: 0.77[95%CI 0.43, 1.37], p=0.37, I<sup>2</sup>= 72%), duration of hospital stay (n=1615; MD: 0.53[95%CI -1.36, 2.41], p=0.58, I<sup>2</sup>=87%), respiratory support (n=1694; OR: 1.51[95%CI 0.77, 2.96], p=0.23, I<sup>2</sup>=84%), duration of mechanical ventilation (n=419; MD: -1.44[95%CI -4.27, 1.40], p=0.32, I<sup>2</sup>=93%), incidence of hyperglycemia (n=516, OR: 0.91[95%CI 0.58, 1.43], p=0.68, I<sup>2</sup>=0%) and infection rate (n=1485, OR: 0.86[95%CI 0.64, 1.16], p=0.33, I<sup>2</sup>=29%).

**Conclusion:** The meta-analysis demonstrated high-dose corticosteroids did not reduce mortality rate. However, high-dose corticosteroids did not pose higher risk of hyperglycemia and infection rate for COVID-19 patients. Due to the inconclusive trial sequential analysis, substantial heterogeneity and low level of evidence, future large-scale randomized clinical trials are warranted to improve the certainty of evidence for the use of high-dose compared to low-dose corticosteroids in COVID-19 patients.

© 2022 Elsevier Inc. All rights reserved.

**Keywords:** Coronavirus; COVID-19; SARS-CoV-2; Corticosteroids; Methylprednisolone; Dexamethasone

## Introduction

In March 2020, the World Health Organization (WHO) had declared coronavirus disease 2019 (COVID-19) as a global

pandemic.<sup>1</sup> As of 1<sup>st</sup> February 2021, more than 100 million people have been diagnosed with COVID-19, and more than 2 million deaths were reported.<sup>2</sup> It is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which belongs to the same family of human coronaviruses as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).<sup>3,4</sup>

<sup>1</sup>Address correspondence to Faculty of Medicine, Department of Anesthesiology, University of Malaya, 50603 Kuala Lumpur, Malaysia. Phone: +60379492411.

E-mail address: [katingng1@um.edu.my](mailto:katingng1@um.edu.my) (K.T. Ng).

The severity of COVID-19 varies from asymptomatic to severe ARDS manifestation, which requires mechanical ventilator support, intensive care unit (ICU) admission, long duration of hospital stay and high mortality rate.<sup>5–7</sup> Evidence suggests that COVID-19 is associated with dysregulated coagulation cascade and excessive release of proinflammatory cytokines,<sup>8–10</sup> leading to diffuse pulmonary injury.<sup>4</sup> Corticosteroids are antiinflammatory and immunomodulatory agents, which had been used as part of the treatment during the outbreak of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012 and Severe Acute Respiratory Syndrome coronavirus-1 (SARS-CoV-1) in 2002.<sup>11,12</sup>

In this current COVID-19 pandemic, corticosteroids use is believed to suppress the inflammatory response of COVID-19 on the lung tissues, leading to less severe lung injury and better recovery outcomes. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, one of the largest COVID-19 trials, demonstrated that dexamethasone reduced the 28-day mortality in COVID-19 patients who required supplemental oxygen.<sup>13</sup> Subsequently, the updated guidelines from the World Health Organization (WHO) and the National Institute of Health (NIH) strongly recommended the use of corticosteroids for COVID-19 patients who require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) or severe COVID-19 patients; albeit advising against its use in mild-to-moderate or nonsevere COVID-19 patients.<sup>14,15</sup> However, the dosage of corticosteroids used among COVID-19 patients varied across different hospitals and countries.<sup>16–27</sup> Several clinical studies were conducted to investigate the role of high-dose versus low-dose corticosteroids as part of the treatment of COVID-19, with conflicting findings.<sup>16–27</sup> At present, the efficacy and safety profile of high-dose versus low-dose corticosteroids remain unclear in the literature. Thus, a systematic review is warranted to synthesize evidence on the use of high-dose and low-dose corticosteroids in COVID-19 patients before any recommendations can be made.

The authors hypothesized that high-dose corticosteroids reduced the mortality rate in COVID-19 patients. The primary objective of this systematic review and meta-analysis was to investigate the clinical effects of high-dose and low-dose corticosteroids on the mortality rate of COVID-19 patients. Secondary aims were to examine the effect of high-dose and low-dose corticosteroids on the ICU admission rate, duration of hospital stay, and the number of patients needing ventilation.

## Materials and Methods

### Study Design

The protocol of this systematic review and meta-analysis was registered prospectively on a public database (PROSPERO- CRD42021249784). The systematic review was reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.<sup>28</sup> The Population, Intervention, Control and Outcomes

(PICO) framework was used to formulate the review questions (Online Supplementary Table A.1). The author-defined high-dose and low-dose corticosteroids were used as the inclusion criteria. The inclusion criteria of high-dose corticosteroids were methylprednisolone >100 mg/day or equivalent and dexamethasone >20 mg/day as high-dose corticosteroids; any dose lower than high-dose corticosteroids was considered as low-dose corticosteroids. Primary outcome of this review was mortality rate. Secondary outcomes included the incidence of ICU admission rate, duration of hospital stay, respiratory support, duration of mechanical ventilation, incidence of hyperglycemia and infection rate.

### Search Strategy

A comprehensive literature search was conducted using Ovid MEDLINE, Ovid EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception until March 1, 2022. No language restriction was applied. The search terms and search strategies are listed in Online Supplementary Table A.2. The authors screened the reference lists of relevant articles to identify potential articles that could be included in the study. Given the data provided online are not extractable, the authors requested raw data from the authors of the potential articles.

### Inclusion and Exclusion Criteria

Inclusion criteria were all randomized controlled trials (RCTs) and observational studies comparing high-dose versus low-dose corticosteroids in hospitalized COVID-19 adult patients (aged 18 years and older). Case reports, case series, reviews (nonsystematic), nonhuman studies, letters and conference abstracts were excluded.

### Study Selection and Data Extraction

All titles, abstracts and full texts screening were independently conducted in accordance with the inclusion and exclusion criteria by two authors (RT and CE). A third author (KN) resolved any disagreements during the screening process. Data extraction was performed by two authors (RT and CE) independently using an online data collection sheet. Any median and interquartile range data were converted to mean and standard deviation.<sup>29</sup> Along with all measured outcomes, other relevant data namely, authors' name, year of publication, study design, sample size, dosage of corticosteroids and duration of corticosteroids used were extracted.

### Quality Assessment

Risk of bias assessment of all included studies was conducted independently by two authors (RT and CE). Newcastle-Ottawa Scale (NOS) was used to assess the quality of observational studies. NOS comprises of three domains, namely selection of study groups, comparability of groups and ascertainment of outcomes in cohort studies.<sup>30</sup> Articles were

considered as high-risk bias and low-risk bias with a score of  $< 7$  and  $\geq 7$ , respectively. All the included RCTs were evaluated with the Cochrane Risk of Bias Assessment Tool, which included assessment of selection bias, performance bias, detection bias, attrition bias, reporting bias and other potential sources of bias.<sup>31</sup> A third author (KN) adjudicated any discrepancy in the process of assessing the quality of the articles. The authors also adopted the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach to assess the quality of evidence for each measured outcomes based on several domains; namely, study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias.<sup>32</sup>

### Data Analysis

Review Manager, version 5.4, was used for statistical analysis. Dichotomous and continuous data were presented in Odds Ratio (OR) and Mean Difference (MD), respectively, with 95% confidence interval (CI). Statistical heterogeneity was assessed using I-square ( $I^2$ ) test.  $I^2$  statistic  $< 40\%$ ,  $40\text{--}60\%$  and  $\geq 60\%$  were considered as low, moderate and high heterogeneity, respectively. A fixed-effect model was used for all the measured outcomes. If substantial heterogeneity was observed, a random-effect model was used for data analysis. Subgroup analysis was performed on the mortality rate based on the types of corticosteroids and respiratory support based on types of mechanical ventilation.

Trial sequential analysis was performed on the primary outcome (mortality) to assess the risk of random error and multiplicity phenomena due to repeated significant testing in meta-analyses<sup>33</sup> (Figure 2). The required meta-analysis information size and adjusted significance thresholds were calculated based on a two-sided sequential analysis-adjusted random effects model, with 5% risk of type 1 error and power of 80%.

## Results

### Study Selection

The search strategy yielded a total of 28,318 articles, and forty-seven articles fulfilled the inclusion and exclusion criteria for full-text screening (Figure 1). Of these, twelve studies (total sample size: 2759 patients) were eligible for qualitative synthesis and data pooling.<sup>16–27</sup> The search identified one ongoing RCT (Online Supplementary Table A.3). Excluded studies are listed in Online Supplementary Table A.4.

### Study Characteristics

The clinical characteristic of each study is tabulated in Table 1. Of all included studies, there were eight observational studies,<sup>16,18–21,23,25,26</sup> one quasi-experimental study,<sup>17</sup> and three RCTs.<sup>22,24,27</sup> The types of corticosteroids used varied across studies; namely, methylprednisolone, dexamethasone, prednisolone, prednisone, and hydrocortisone. Three studies solely used one type of corticosteroids,<sup>16,24,27</sup> eight studies

used more than one type of corticosteroids,<sup>17,18,20–23,25,26</sup> and one study did not specify the type of corticosteroid used.<sup>19</sup> The respective doses of each type of corticosteroids were methylprednisolone  $<0.5$  mg/kg/day-to-500 mg/day, dexamethasone 6 mg/day-to-40 mg/day, hydrocortisone  $<200$  mg/day-to- $\geq 300$  mg/day, and prednisone  $<0.5$  mg/kg/day- to  $>0.5$  mg/kg/day. The duration of low-dose and high-dose corticosteroids regimens varied from 3 days to day of hospital discharge.

### Quality Assessment

The summary of risk of bias assessment (The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool) and GRADE approach are presented in Online Supplementary Table A.5 and Table 2, respectively. All observational studies were overall low risk of bias.<sup>16,18–21,23,26</sup> Among all the included observational studies, four of them did not match of the clinical characteristics between high and low dose corticosteroids groups.<sup>18,20,21,23</sup> Three RCT was assessed as low risk of bias<sup>22,24,27</sup> while the other one RCT was high risk of bias due to lack of random allocation of participants into high dose and low dose corticosteroids groups, which constituted potential selection bias.<sup>17</sup>

### Primary Outcome

#### Mortality Rate

Eleven studies ( $n=2632$ ) reported the mortality rate of COVID-19 patients after the administration of high-dose and low-dose corticosteroids (Table 3). The mortality rate for high-dose and low-dose groups were 29% and 22%, respectively. Among these studies, there were three RCTs,<sup>22,24,27</sup> one quasi experimental study<sup>17</sup> and seven observational studies.<sup>16,19–21,23,25,26</sup> The pooled analysis demonstrated no significant difference in the reduction of mortality rate between high-dose and low-dose corticosteroids (OR: 1.07 [95%CI 0.67, 1.72],  $p=0.77$ ,  $I^2=76\%$ , certainty of evidence=very low).

In the subgroup analysis comparing between methylprednisolone (high-dose group) versus dexamethasone (low-dose group), four studies ( $n= 1091$ ) were included in meta-analysis<sup>17,21,22,25</sup> (Figure 3). Our result demonstrated no significant difference between high-dose methylprednisolone and low-dose dexamethasone (OR:0.84 [95 CI% 0.34, 2.07],  $p=0.70$ ,  $I^2 =82\%$ ). In the trial sequential analysis, the minimum required information size for mortality was 13024 patients. In the current meta-analysis, with 2632 patients, only 20% of the required information size was available to detect or reject a relative risk reduction of 20% mortality rate, based on a 5% risk of Type 1 error (two-sided), a power of 80%, and an incidence in the control arm of 24.5%, with a model variance-based heterogeneity correction.




Figure 1. PRISMA Flow Diagram

### Secondary outcomes

#### ICU Admission Rate

Data of seven studies (n= 1544) (two RCTs,<sup>24,27</sup> one quasi-experimental study<sup>17</sup> and four observational studies<sup>18,21,25,26</sup> were pooled for meta-analysis (Table 3). The results revealed COVID-19 patients with high-dose corticosteroids were not associated with lower ICU admission rate than the low-dose corticosteroids group, as compared to low-dose corticosteroids (OR: 0.77[95%CI 0.43, 1.37], p=0.37, I<sup>2</sup>= 72%, certainty of evidence = very low).

#### Duration of Hospital Stay (days)

Seven studies (n=1215) (three RCT<sup>22,24,27</sup> and four observational studies<sup>16,23,25,26</sup>) assessed the duration of hospital stay between the high-dose and low-dose corticosteroids groups

(Table 3). No significant difference was observed (MD: 0.53 [95%CI -1.36, 2.41], p=0.58, I<sup>2</sup>=87%, certainty of evidence = very low).

#### Respiratory Support

Seven studies (n=1694) (three RCTs,<sup>22,24,27</sup> one quasi-experimental study<sup>17</sup> and three observational studies<sup>23,25,26</sup> reported the number of people requiring respiratory support (Table 3). There was no significant difference observed between high-dose and low-dose corticosteroids (OR: 1.51 [95%CI 0.77, 2.96], p=0.23, I<sup>2</sup>=84%, certainty of evidence = very low).

Subgroup analysis was performed based on the type of mechanical ventilations, noninvasive mechanical ventilation (n=219) and mechanical ventilation (n=1082). The data analysis revealed no significant difference between high-dose and

Table 1  
Clinical characteristics of included studies

No.	Author	Year	Sample size	Study Design	Types of Corticosteroids	Dosage		Duration of corticosteroids used (days)	
						Low Dose Corticosteroids	High Dose Corticosteroids	Low Dose Corticosteroids	High Dose Corticosteroids
1	Huang <sup>16</sup>	2020	28	Observational study	Methylprednisolone	Methylprednisolone $\leq 1.5\text{mg/kg/d}$			
					Methylprednisolone $> 1.5\text{mg/kg/d}$	6.8 $\pm$ 2.1	11.6 $\pm$ 6.3		
2	Fatima <sup>17</sup>	2020	100	Quasi experimental, interventional study	Methylprednisolone, dexamethasone	Dexamethasone 8mg/day			
3	Munoz <sup>18</sup>	2020	127	Observational study	Methylprednisolone 1mg/kg/day Methylprednisolone, dexamethasone	5 Dexamethasone 6mg/day	5		
4	Monreal <sup>19</sup>	2020	573	Observational study	Methylprednisolone 125-250mg/day NR	10 0.5-1.5mg/kg/day of methylprednisolone equivalent	3 250-1000mg/day of		
5	Zúñiga <sup>20</sup>	2021	132	Observational study	methylprednisolone equivalent Methylprednisolone, dexamethasone	NR <1.5mg/kg/day of methylprednisolone or dexamethasone equivalent	NR $\geq 1.5\text{mg/kg/day}$ of		
					methylprednisolone or dexamethasone equivalent	NR	3		
6	Pinzón <sup>21</sup>	2021	216	Observational study	Methylprednisolone, dexamethasone	Dexamethasone 6mg/day			
7	Ranjbar <sup>22</sup>	2021	93	RCT	Methylprednisolone 250-500mg/day Methylprednisolone, dexamethasone	7-10 Dexamethasone 6mg/day	3		
8	Gundogdu <sup>23</sup>	2021	400	Observational study	Methylprednisolone 2mg/kg/d Methylprednisolone, dexamethasone	10 Dexamethasone 8mg/day; Methylprednisolone 80mg/day	5		
9	Toroghi <sup>24</sup>	2021	93	RCT	Methylprednisolone 1g/day Dexamethasone	NR Dexamethasone 8mg/day	NR Dexamethasone 24mg/day	Up to 10 days or until hospital discharge	
10	Mora-Luján <sup>25</sup>	2021	682	Observational study	Methylprednisolone, Dexamethasone	Dexamethasone 6mg/day			
					Methylprednisolone $\geq 100\text{ mg/day}$	10	3		
11	Batirel <sup>26</sup>	2021	126	Observational study	Methylprednisolone, Dexamethasone	Dexamethasone 6mg/day equivalent			
12	Taboada <sup>27</sup>	2021	200	RCT	Methylprednisolone 250mg/day Dexamethasone	NR Dexamethasone 6mg/day	NR Dexamethasone 20mg/day	10	5

NR: Not Reported

RCT: Randomized controlled trial



Table 2  
Grading of Recommendations, Assessment, Development and Evaluations of each outcome

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	High Dose Corticosteroids	Low Dose Corticosteroids	Relative (95% CI)	Absolute (95% CI)		
<b>Mortality Rate</b>												
11	observational studies	not serious	very serious <sup>a</sup>	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	305/1064 (28.7%)	344/1568 (21.9%)	OR 1.07 (0.67 to 1.72)	12 more per 1,000 (from 61 fewer to 106 more)	⊕○○○ Very low	
<b>ICU Admission Rate</b>												
7	observational studies	serious <sup>a</sup>	very serious <sup>a</sup>	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	130/663 (19.6%)	180/881 (20.4%)	OR 0.77 (0.43 to 1.37)	39 fewer per 1,000 (from 105 fewer to 36 more)	⊕○○○ Very low	
<b>Duration of Hospital Stay</b>												
7	observational studies	not serious	very serious <sup>a</sup>	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	651	964	-	MD 0.53 higher (1.36 lower to 2.41 higher)	⊕○○○ Very low	
<b>Respiratory Support</b>												
7	observational studies	not serious	very serious <sup>a</sup>	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	247/708 (34.9%)	197/886 (20.0%)	OR 1.51 (0.77 to 2.96)	74 more per 1,000 (from 39 fewer to 225 more)	⊕○○○ Very low	
<b>Duration of Mechanical Ventilation</b>												
3	observational studies	not serious	very serious <sup>a</sup>	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	207	212	-	MD 1.44 lower (4.27 lower to 1.4 higher)	⊕○○○ Very low	
<b>Hyperglycaemia</b>												
3	randomised trials	serious <sup>a</sup>	not serious	not serious	not serious	all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a</sup>	113/268 (42.2%)	92/248 (37.1%)	OR 0.91 (0.58 to 1.43)	22 fewer per 1,000 (from 116 fewer to 87 more)	⊕⊕⊕⊕ High	
<b>Infection Rate</b>												
5	observational studies	not serious	not serious	not serious	not serious	publication bias strongly suspected all plausible residual confounding would suggest spurious effect, while no effect was observed <sup>a,c</sup>	94/645 (14.6%)	145/840 (17.3%)	OR 0.86 (0.64 to 1.16)	20 fewer per 1,000 (from 55 fewer to 22 more)	⊕⊕○○ Low	

CI: confidence interval; MD: mean difference; OR: odds ratio

**Explanations**

- a. Substantial heterogeneity
- b. Funnel plot asymmetrical suggestive of publication bias
- c. Different dosages and types of corticosteroids used across all the included studies
- d. 1 high risk of bias study

CI: confidence interval; MD: mean difference; OR: odds ratio

**Explanations**

- a. Substantial heterogeneity
- b. Funnel plot asymmetrical suggestive of publication bias
- c. Different dosages and types of corticosteroids used across all the included studies
- d. 1 high risk of bias study

low-dose corticosteroids in the noninvasive mechanical ventilation subgroup (OR 1.18[95%CI 0.61, 2.30], p=0.62, I<sup>2</sup>=0%), as well as the invasive mechanical ventilation subgroup (OR 2.78[95%CI 0.85, 9.08], p=0.09, I<sup>2</sup>=94%).

*Duration of Mechanical Ventilation*

Three studies (n=419) (two RCTs<sup>24,27</sup> and one observational study<sup>26</sup> demonstrated no significant difference in the duration of mechanical ventilation between high-dose and low-dose

corticosteroids groups (MD: -1.44[95%CI -4.27, 1.40], p=0.32, I<sup>2</sup>=93%, certainty of evidence = very low) (Table 3).

*Hyperglycemia*

Three studies (n=516) (one RCT,<sup>27</sup> one quasiexperimental study<sup>17</sup> and one observational study<sup>21</sup>), showed no significant difference in the incidence of hyperglycemia between the high-dose and low-dose corticosteroids groups (OR: 0.91 [95%CI 0.58, 1.43], p=0.68, I<sup>2</sup>=0%, certainty of evidence = high) (Table 3).

Table 3  
Summary findings for primary and secondary outcomes

No.	Outcomes	Trials	N	I <sup>2</sup> (%)	Effect Model	MD/OR (95% CI)	p-value
1	Mortality	11	2632	76%	REM	1.07 (0.67, 1.72)	0.77
1.1	Subgroup analysis by type of corticosteroids	4	1091	82	REM	0.84 (0.34, 2.07)	0.70
1.2	Methylprednisolone (High Dose) VS Dexamethasone (Low Dose)	7	1541	76	REM	1.23 (0.65, 2.33)	0.77
	Methylprednisolone/Dexamethasone equivalent						
	Heterogeneity: Tau <sup>2</sup> = 0.46; Chi <sup>2</sup> = 42.06, df = 10 (P < 0.00001); I <sup>2</sup> = 76%						
	Test for overall effect: Z = 0.29 (P = 0.77)						
	Test for subgroup differences: Chi <sup>2</sup> = 0.45, df = 1 (P = 0.50), I <sup>2</sup> = 0%						
2	ICU Admission	7	1544	72	REM	0.77 (0.43, 1.37)	0.37
	Heterogeneity: Tau <sup>2</sup> = 0.41; Chi <sup>2</sup> = 21.51, df = 6 (P = 0.001); I <sup>2</sup> = 72%						
	Test for overall effect: Z = 0.89 (P = 0.37)						
3	Duration of Hospital Stay	7	1215	87	REM	0.53 (-1.36, 2.41)	0.58
	Heterogeneity: Tau <sup>2</sup> = 5.17, Chi <sup>2</sup> = 44.54, df = 6 (P < 0.00001); I <sup>2</sup> = 87%						
	Test for overall effect: Z = 0.55 (P = 0.58)						
4	Respiratory Support	7	1694	84	REM	1.51 (0.77, 2.96)	0.23
4.1	Subgroup analysis by type of mechanical ventilations	3	393	69	REM	0.95 (0.35, 2.57)	0.93
4.2	Mixed Mechanical Ventilation	2	219	0	REM	1.18 (0.61, 2.30)	0.62
4.3	Non-invasive Mechanical Ventilation	3	1082	94	REM	2.78 (0.85, 9.08)	0.09
	Invasive Mechanical Ventilation						
	Heterogeneity: Tau <sup>2</sup> = 0.64, Chi <sup>2</sup> = 38.09, df = 6 (P = 0.00001); I <sup>2</sup> = 84%						
	Test for overall effect: Z = 1.21 (P = 0.23)						
	Test for subgroup differences: Chi <sup>2</sup> = 2.04, df = 2 (P = 0.36), I <sup>2</sup> = 1.9%						
5	Duration of Mechanical Ventilation	3	419	93	REM	-1.44 (-4.27, 1.40)	0.32
	Heterogeneity: Tau <sup>2</sup> = 5.81, Chi <sup>2</sup> = 27.17, df = 2 (P = 0.00001); I <sup>2</sup> = 93%						
	Test for overall effect: Z = 0.99 (P = 0.32)						
6	Hyperglycemia	3	516	0	FEM	0.91 (0.58, 1.43)	0.68
	Heterogeneity: Chi <sup>2</sup> = 0.31, df = 2 (P = 0.86); I <sup>2</sup> = 0%						
	Test for overall effect: Z = 0.41 (P = 0.68)						
7	Infection Rate	5	1485	29	FEM	0.86 (0.64, 1.16)	0.33
	Heterogeneity: Chi <sup>2</sup> = 4.21, df = 3 (P = 0.24); I <sup>2</sup> = 29%						
	Test for overall effect: Z = 0.97 (P = 0.33)						

FEM: Fixed-Effect Model; REM: Random-Effect Model; MD: Mean Difference; OR: Odd Ratio; VS: Versus

### Infection Rate

Five studies (n=1485) (one RCT,<sup>27</sup> one quasiexperimental study<sup>17</sup> and three observational studies<sup>19,21,23</sup> were pooled for meta-analysis. The results revealed no significant difference between high-dose and low-dose corticosteroids in infection rate (OR: 0.86[95%CI 0.64, 1.16], p=0.33, I<sup>2</sup>=29%, certainty of evidence = low) (Table 3).

### Discussion

To the best of the authors' knowledge, this was the first meta-analysis comparing the efficacy and safety profile of high-dose versus low-dose corticosteroids in COVID-19 patients. The meta-analysis demonstrated no significant differences in mortality rate, ICU admission rate, duration of hospital stays, number of patients requiring respiratory support, duration of mechanical ventilation, incidence of hyperglycemia and infection rate between the high-dose and low-dose corticosteroids groups among COVID-19 patients. The certainty of evidence for all measured outcomes ranged very low-to-high due to observational studies, inconsistency, publication bias and dose-response gradient.

In the meta-analysis, the pooled data demonstrated that high-dose corticosteroids were not superior to low-dose corticosteroids in the reduction of mortality rate in COVID-19 patients. The non-significant result could have been due to multifactorial causes; namely, different types, dosages and regimens (duration) of corticosteroids. In addition, the current meta-analysis did not achieve the minimum required information size for a conclusive finding. A recent study by the COVID STEROID 2 trial group involving COVID-19 patients with severe hypoxemia, 12 mg/d compared with 6 mg/d dexamethasone did not result in statistically significantly more days alive without life support at 28 days.<sup>34</sup> However, in its preplanned Bayesian analysis of the trial, they found high probabilities of benefit with dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxemia on all outcomes, including the days alive without life support and mortality at days 28 and 90. They also found low probabilities of clinically important harm with 12 mg dexamethasone for all outcomes.<sup>35</sup> In this study, the 2 doses used still were considered low-dose, but there was evidence showing lower mortality in the higher-dose group.

Corticosteroids inhibit proinflammatory protein synthesis (interleukin-6, interleukin-8, tumor necrosis factor,






Figure 2. Trial Sequential Analysis (TSA) for mortality rate

interferon  $\gamma$ ) and induce the production of antiinflammatory proteins.<sup>36,37</sup> However, it comes with some adverse events; namely, hyperglycemia, hypernatremia and neuromuscular weakness.<sup>36–38</sup> While 7.5 mg of prednisone or equivalent slowly may activate the effect of corticosteroids, the use of >100 mg of prednisone equivalent and pulse therapy ( $\geq 250$  mg prednisone equivalent) can rapidly saturate the cytoplasmic glucocorticoids receptors to activate fast onset of antiinflammatory action.<sup>36</sup>

A prospective study showed 3 days of high-dose pulsed corticosteroids therapy (at least 125 mg of methylprednisolone or its equivalent dexamethasone), significantly increased survival rate in COVID-19 patients.<sup>20</sup> Others reported similar results with the use of 250 mg/day of methylprednisolone that reduced mortality rate and shortened duration of hospitalization in COVID-19-induced ARDS in patients.<sup>39,40</sup> However, Tataki and colleagues reported that COVID-19 patients with an excessively high dose of pulsed corticosteroids therapy




Figure 3. Forest Plots of Mortality Rate (Subgroup analysis based on different types of corticosteroids used)

(1000 mg/day of methylprednisolone) were associated with a poorer prognosis.<sup>41</sup> Thus, the optimal dosage of pulsed corticosteroids therapy for COVID-19 patients warrants future adequately powered randomized trials for more clarity and evidence.

The nonsignificant finding of mortality rate was similar to a meta-analysis by Cano et al. comparing two groups (high-dose corticosteroids vs no corticosteroids; low-dose corticosteroids vs no corticosteroids).<sup>42</sup> In the authors' meta-analysis, they performed subgroup analysis based on different types of corticosteroids. They found that the mortality rate in the high-dose corticosteroids group (methylprednisolone group) was not significantly lower than the low-dose corticosteroids group (dexamethasone group). In other words, the mortality rate of COVID-19 patients did not improve with the use of methylprednisolone, while it is believed that methylprednisolone has better lung penetration.<sup>43</sup> Ko and coworkers reported that methylprednisolone (1 mg/kg/d) had a significantly greater mortality benefit than dexamethasone (6mg/day) in COVID-19 mechanically ventilated patients.<sup>44</sup> Ranjbar et al. compared methylprednisolone (2 mg/kg/day) and dexamethasone (6 mg/day) in hospitalized COVID-19 patients, and found that those who received methylprednisolone had better clinical outcomes.<sup>22</sup> Due to the limited number of studies comparing methylprednisolone and dexamethasone, it is premature to claim the superiority of either methylprednisolone or dexamethasone in treating pneumonia in COVID-19 patients. Therefore, future adequately powered studies can evaluate the efficacy of different types of corticosteroids in the treatment of COVID-19 pneumonia.

Despite the desirable antiinflammatory effect of corticosteroids, the safety profile of corticosteroids use in COVID-19 patients is inconclusive.<sup>17,19,21,23,27,45,46</sup> The CoDEX trial demonstrated that 20 mg of dexamethasone did not significantly increase the risk of new infections, bacteremia, or any increased insulin use for hyperglycemia, as compared to a standard-care group.<sup>46</sup> A meta-analysis revealed that the pulsed corticosteroids (>250 mg prednisone) were not associated with increased risk of side effects such as cardiac events, hyperglycemia, infections, hypertension, edema, gastrointestinal and psychiatric adverse events.<sup>47</sup> Due to the limited data available, the authors only managed to pool the data for the incidence of hyperglycemia and infection rate between the high- and low-dose corticosteroids groups. The meta-analysis revealed no augmented risk of hyperglycemia and infection episodes in COVID-19 patients who received high-dose corticosteroids. Monedero and colleagues also reported moderate-to-high-dose corticosteroids ( $\geq 1$  mg/kg/d methylprednisolone or  $\geq 0.12$  mg/kg/d dexamethasone) were not associated with higher risk of medical or infectious complications.<sup>45</sup>

The pooled meta-analysis demonstrated no significant reduction of the ICU admission rate in the high-dose corticosteroids group. Of note, many confounding factors; namely, underlying morbidities, obesity, baseline functional status, and severity of organ failure introduced bias to the findings. However, Pareja et al. found that high-dose corticosteroids (equivalent to  $\geq 200$  mg of methylprednisolone) were associated with

lower mortality rate and ICU admission.<sup>48</sup> Similarly, Pinzo'n and Munoz found that high-dose corticosteroids (125–500 mg/day of methylprednisolone) significantly reduced the ICU admission as compared to a low-dose group.<sup>18,21</sup> This could have been due to the patients who received corticosteroids were those who required oxygen support or had more severe COVID-19 disease, which could denote more severe pulmonary involvement and inflammation. With higher-dose corticosteroids, it could activate faster onset of antiinflammatory action to achieve favorable outcomes.

In this review, there were no significant differences observed in the duration of hospital stay, the number of patients requiring respiratory support and the duration of mechanical ventilation. Different durations of corticosteroids regimens was used across all included studies, which introduced variances to the findings.<sup>16–27</sup> In contrast, a triple-blinded RCT established that high-dose corticosteroids significantly reduced the length of hospital stay and the number of patients requiring respiratory support (2 mg/kg methylprednisolone) as compared to low-dose corticosteroids (6 mg dexamethasone).<sup>22</sup> High-dose corticosteroids generally were used for fewer than 10 days in the reported studies, and were associated with a shorter duration of hospitalization and ventilation support.<sup>17,21,22,44,45,48</sup>

Low-dose corticosteroids commonly are used in surgery to minimize postoperative nausea and vomiting and as an adjunct to part of the multimodal analgesia. The dose-dependent use of corticosteroids for surgery comes with its adverse effects; namely, incidence of hyperglycemia, surgical site infection, myocardial infarction and mortality rate.<sup>49</sup> The vaccination rate of the low-income countries remains low due to various challenges; namely, limited vaccine supply and vaccine hesitancy.<sup>50</sup> With this, there are more and more COVID-19 patients presenting for surgery. In this review, subgroup analysis based on surgical and nonsurgical COVID-19 patients receiving high-dose versus low-dose corticosteroids was not conducted due to lack of data available for pooling. Thus, the findings may not generalize to COVID-19 patients undergoing surgery. Due to the paucity of evidence, the dosage of corticosteroids among surgical COVID-19 patients may be considered based on the severity of COVID-19 infection and types of surgery involving airway manipulation.

The review had several limitations. The main limitation was the inconsistency of the dosage, types and regimens of high-dose versus low-dose corticosteroids across all the reported studies,<sup>16–27</sup> which may have contributed to a high degree of heterogeneity. Adverse events from high-dose and low-dose corticosteroids were not extensively reported in all the included studies. The outcomes of long-term follow up for high-dose and low-dose corticosteroids COVID-19 survivors are needed to determine any complication of corticosteroids in the relapse of ARDS or pneumonia. Subgroup analysis based on the severity of COVID-19 patients (ICU and non-ICU) was not performed due to limited data available for data pooling. In addition, the nature of observational studies with small sample sizes may introduce bias to the findings. Therefore, more adequately powered RCTs should be carried out to evaluate

the efficacy of types, dosage, and duration of corticosteroids in the treatment of COVID-19.

In conclusion, this meta-analysis showed that low-dose corticosteroids were as effective as high-dose corticosteroids in the reduction of COVID-19 mortality rate. In view of substantial heterogeneity and low level of evidence, future adequately powered RCTs are warranted to increase certainty of evidence and minimize heterogeneity.

## Acknowledgements

We thank Dr Enric Monreal for data sharing upon request.

## Funding

This research did not receive specific grant from funding agencies in the public, commercial, or not-for profit sectors.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

## Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:[10.1053/j.jvca.2022.05.011](https://doi.org/10.1053/j.jvca.2022.05.011).

## References

- 1 Organización Mundial de la Salud. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Who.int. WHO Director General's speeches. 2020. Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>
- 2 Wang C, Wang Z, Li W, et al. COVID-19 in early 2021: current status and looking forward. *Sig Transduct Target Ther* 2021;6(1):114. <https://doi.org/10.1038/s41392-021-00527-1>.
- 3 House NNC, Palissery S, Sebastian H. Corona Viruses: A Review on SARS, MERS and COVID-19. *Microbiol Insights*. 2021;14:1–8. <https://doi.org/10.1177/11786361211002481>.
- 4 Johns M, George S, Taburyanskaya M, et al. A Review of the Evidence for Corticosteroids in COVID-19. *J Pharm Pract* 2021;1–12. <https://doi.org/10.1177/0897190021998502>.
- 5 Elez Kurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. *Sci Rep* 2021;11(1):1–9. <https://doi.org/10.1038/s41598-021-82862-5>.
- 6 van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. *Crit Care* 2020;24(1):1–22. <https://doi.org/10.1186/s13054-020-03400-9>.
- 7 Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Med* 2020;8(12):1201–8. [https://doi.org/10.1016/S2213-2600\(20\)30370-2](https://doi.org/10.1016/S2213-2600(20)30370-2).
- 8 Ragab D, Salah Eldin H, Taemah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol* 2020;11:1446. <https://doi.org/10.3389/fimmu.2020.01446>.
- 9 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 10 Rodríguez-Baño J, Pachón J, Carratalá J, Ryan P, Jarrín I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyper-inflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol and Infect* 2021;27(2):244–52. <https://doi.org/10.1016/j.cmi.2020.08.010>.
- 11 Hu T, Liu Y, Zhao M, et al. A comparison of COVID-19, SARS and MERS. *PeerJ* 2020;8:e9725. <https://doi.org/10.7717/peerj.9725>.
- 12 Ahmed MH, Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. *SN Compr Clin Med* 2020;2(12):1–10. <https://doi.org/10.1007/s42399-020-00610-8>.
- 13 RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 2021. *The New England journal of medicine* [Internet] 2021;384(8):693–704. <https://doi.org/10.1056/NEJMoa2021436>.
- 14 Corticosteroids for COVID-19 [Internet]. World Health Organization; 2020 Sept 2. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1>
- 15 Therapeutic Management of Hospitalized Adults with COVID-19 [Internet]. National Institutes of Health | COVID-19 Treatment Guidelines. [Updated 2022 Feb 24] Available from: <https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults---therapeutic-management/>
- 16 Huang H, Song B, Xu Z, et al. Predictors of Coronavirus Disease 2019 Severity: A Retrospective Study of 64 Cases. *Jpn J Infect Dis* 2021;74(1):54–60. <https://doi.org/10.7883/yoken.JIID.2020.298>.
- 17 Fatima SA, Asif M, Khan KA, et al. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. *Ann Med Surg* 2020;60:413–6. <https://doi.org/10.1016/j.amsu.2020.11.027>.
- 18 García MS, Santos SSM, Cebolla BT, et al. High-dose versus low-dose corticosteroid treatment strategy in patients hospitalised with COVID-19: effect on ICU admission rate. *Rev OFIL ILAPHAR* 2021;31(1):13–7; Available from: <https://ilaphar.org/wp-content/uploads/2021/02/Original-1-ILAPHAR-31-1.pdf>.
- 19 Monreal E, de la Maza SS, Natera-Villalba E, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. *Eur J Clin Microbiol Infect Dis* 2021;40(4):761–9. <https://doi.org/10.1007/s10096-020-04078-1>.
- 20 Lopez Zuniga MA, Moreno-Moral A, Ocana-Granados A, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. *PLoS One* 2021;16(1):e0243964. <https://doi.org/10.1371/journal.pone.0243964>.
- 21 Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. *PLoS one* 2021;16(5):e0252057. <https://doi.org/10.1371/journal.pone.0252057>.
- 22 Ranjbar K, Moghadami M, Mirahmadzadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infect Dis* 2021;21(1):337. <https://doi.org/10.1186/s12879-021-06045-3>.
- 23 Gundogdu O, Demir B, Coskun CO, et al. Efficacy of pulse steroid therapy in patients critically ill with COVID-19. *Bratisl Lek Listy* 2021;122(11):793–8. [https://doi.org/10.4149/BLL\\_2021\\_126](https://doi.org/10.4149/BLL_2021_126).
- 24 Toroghi N, Abbasian L, Nourian A, et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. *Pharmacol Rep* 2022;74(1):229–40. <https://doi.org/10.1007/s43440-021-00341-0>.
- 25 Mora-Luján JM, Tuells M, Montero A, et al. High-dose methylprednisolone pulses for 3 days vs. Low-dose dexamethasone for 10 days in severe, non-critical covid-19: A retrospective propensity score matched analysis. *J Clin Med* 2021;10(19):4465. <https://doi.org/10.3390/jcm10194465>.
- 26 Batirel A, Demirhan R, Eser N, et al. Pulse steroid treatment for hospitalized adults with COVID-19. *Turk J Med Sci* 2021;51(5):2248–55. <https://doi.org/10.3906/sag-2101-243>.
- 27 Taboada M, Rodríguez N, Varela PM, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial. *Eur Respir J* 2021. <https://doi.org/10.1183/13993003.02518-2021>.

- 28 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097. <https://doi.org/10.1371/journal.pmed.1000097>.
- 29 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005;5:13. <https://doi.org/10.1186/1471-2288-5-13>.
- 30 Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
- 31 Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. <https://doi.org/10.1136/bmj.d5928>.
- 32 Schünemann H, Brozek J, Guyatt G, et al. GRADE Handbook [Internet]. [Updated 2013 October]. Available from: <https://gdt.gradepro.org/app/handbook/handbook.html>
- 33 Thorlund K, Engstrøm J, Wetterslev J, et al. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention research, Copenhagen, Denmark. 2011 [Updated 2017]. Available from: <https://ctu.dk/tsa/>
- 34 The COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA*. 2021;326(18):1807–17. <https://doi.org/10.1001/jama.2021.18295>.
- 35 Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a preplanned, secondary Bayesian analysis of the COVID STEROID 2 trial. *Intensive Care Med* 2022;48(1):45–55. <https://doi.org/10.1007/s00134-021-06573-1>.
- 36 Stahn C, Buttgerit F. Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol* 2008;4(10):525–33. <https://doi.org/10.1038/ncprheum0898>.
- 37 Buttgerit F, Burmester G-R, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. *Lancet* 2005;365(9461):801–3. [https://doi.org/10.1016/S0140-6736\(05\)17989-6](https://doi.org/10.1016/S0140-6736(05)17989-6).
- 38 Johns M, George S, Taburyanskaya M, et al. A Review of the Evidence for Corticosteroids in COVID-19. *J Pharm Pract* 2021. <https://doi.org/10.1177/0897190021998502>.
- 39 Edalatfard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. *Eur Respir J* 2020;56(6). <https://doi.org/10.1183/13993003.02808-2020>.
- 40 Espinosa-Solano M, Gonzalez-Vergara D, Ferrer-Galvan M, et al. Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before--After Study (CortiCOVID Study). *Open Respiratory Archives*. 2021;3(2):100086. <https://doi.org/10.1016/j.opresp.2021.100086>
- 41 Takaki M, Ichikado K, Kawamura K, et al. The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study. *Crit Care* 2017;21(1):1–7. <https://doi.org/10.1186/s13054-017-1723-0>.
- 42 Cano EJ, Fuentes XF, Campioli CC, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. *Chest J* 2021;159(3):1019–40. <https://doi.org/10.1016/j.chest.2020.10.054>.
- 43 Vichyanond P, Irvin CG, Larsen GL, et al. Penetration of corticosteroids into the lung: Evidence for a difference between methylprednisolone and prednisolone. *J Allergy Clin Immunol* 1989;84(6):867–73. [https://doi.org/10.1016/0091-6749\(89\)90381-3](https://doi.org/10.1016/0091-6749(89)90381-3).
- 44 Ko JJ, Wu C, Mehta N, et al. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. *J Intensive Care Med* 2021;36(6):673–80. <https://doi.org/10.1177/0885066621994057>.
- 45 Monedero P, Gea A, Castro P, et al. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. *Crit Care* 2021;25(1):2. <https://doi.org/10.1186/s13054-020-03422-3>.
- 46 Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA* 2020;324(13):1307–16. <https://doi.org/10.1001/jama.2020.17021>.
- 47 Edel Y, Avni T, Shepshelovich D, et al. The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. *Semin Arthritis Rheum* 2020;50(3):534–45. <https://doi.org/10.1016/j.semarthrit.2019.11.006>.
- 48 Pascual Pareja JF, García-Caballero R, Soler Rangel L, et al. Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2. *Med Clin (Barc)* 2021;156(5):221–8. <https://doi.org/10.1016/j.medcli.2020.11.004>.
- 49 Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, et al. "Coronavirus Pandemic (COVID-19)". *Our World in Data*. 2020 [Updated 2022 Apr]. Available from: <https://ourworldindata.org/coronavirus>
- 50 Ng KT, Van Paassen J, Langan C, et al. The efficacy and safety of prophylactic corticosteroids for the prevention of adverse outcomes in patients undergoing heart surgery using cardiopulmonary bypass: a systematic review and meta-analysis of randomized controlled trials. *Eur J Cardiothorac Surg* 2020;57:620–7; <https://doi.org/10.1093/ejcts/ezz325>.